Sadhana Jackson
National Institute of Neurological Disorders and Stroke (NINDS) · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sadhana Jackson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:11 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07416188 · Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent GlioblastomaNational Institute of Neurological Disorders and Stroke (NINDS) · recruiting · Recurrent Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Relapsed Cancer · principal investigator
- Ph1NCT05413304 · Abemaciclib Neuropharmacokinetics of Diffuse Midline Glioma Using Intratumoral MicrodialysisNational Cancer Institute (NCI) · active not recruiting · Glioma · principal investigator
- Ph1NCT03493932 · Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeNational Institute of Neurological Disorders and Stroke (NINDS) · completed · Glioblastoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Modulating BBB Permeability in Malignant GliomaZIANS009417 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · fiscal years 2020 to 2025 · $1,568,447 awarded in 2025Same name and institution; not confirmed by an ID
- Modulating BBB Permeability in Malignant GliomaZIABC011686 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2016 to 2019 · $440,662 awarded in 2019Same name and institution; not confirmed by an ID
- Brain Interstitium Temozolomide Concentration Pre and Post RegadenosonZIABC011685 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2016 to 2018 · $51,678 awarded in 2018Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in glioma, ranked by citations from NIH iCite, fetched 2026-11-12 12:11 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- The effect of an adenosine A2A agonist on intra-tumoral concentrations of temozolomide in patients with recurrent glioblastoma.Fluids Barriers CNS · 201863 citationsRCR 2.7
- Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma.Neuro Oncol · 200441 citationsRCR 1.0
- Superfractionated radiotherapy in grade III, IV intracranial gliomas.Int J Radiat Oncol Biol Phys · 198836 citationsRCR 1.2
- Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade.Neurosurgery · 201931 citationsRCR 1.1
- Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.Neuro Oncol · 200426 citationsRCR 0.7
- 7 citationsRCR 0.7